Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.

Ikonomidis I, Michalopoulou E, Pavlidis G, Nikolaou PE, Katogiannis K, Prentza V, Thymis J, Vlachomitros D, Katsanaki E, Kostelli G, Korakas E, Pliouta L and 7 more

Show all authors

Kountouri A, Kypraios D, Dimitroulopoulos D, Oikonomou E, Siasos G, Papanikolaou IS, Lambadiari V

Journal of hypertension7 Apr 2026

PMID42201656DOI10.1097/hjh.0000000000004311PepBankPUB-42201656

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with T2DM and MASLD, dulaglutide improved GLS more than dapagliflozin.
In plain wordsDulaglutide was linked to greater GLS improvement than dapagliflozin in patients with diabetes and fatty liver.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGLS improvement
Study
n = 42
Comparator
dapagliflozin
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
GLS improvement
22.6%
dulaglutide
GLS improvement
8.5%
dapagliflozin
Source sentences
Summary
Dulaglutide showed greater improvement in GLS (22.6% vs. 8.5%, vs. 5.9%, P = 0.015) and PBR (P = 0.037) than dapagliflozin and DDP-4i.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
Report a problemFND-4220165601
02HumanObservational studyEfficacy outcome
In patients with T2DM and MASLD, dulaglutide improved PBR more than dapagliflozin.
In plain wordsDulaglutide was linked to greater PBR improvement than dapagliflozin in patients with diabetes and fatty liver.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePBR improvement
Study
n = 42
Comparator
dapagliflozin
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide showed greater improvement in GLS (22.6% vs. 8.5%, vs. 5.9%, P = 0.015) and PBR (P = 0.037) than dapagliflozin and DDP-4i.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
Report a problemFND-4220165603
03HumanObservational studyEfficacy outcome
In patients with T2DM and MASLD, dulaglutide improved GLS more than DDP-4i.
In plain wordsDulaglutide was linked to greater GLS improvement than DDP-4i in patients with diabetes and fatty liver.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGLS improvement
Study
n = 41
Comparator
DDP-4i
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
GLS improvement
22.6%
dulaglutide
GLS improvement
5.9%
DPP-4i
Source sentences
Summary
Dulaglutide showed greater improvement in GLS (22.6% vs. 8.5%, vs. 5.9%, P = 0.015) and PBR (P = 0.037) than dapagliflozin and DDP-4i.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
Report a problemFND-4220165602
04HumanObservational studyEfficacy outcome
In patients with T2DM and MASLD, dulaglutide improved PBR more than DDP-4i.
In plain wordsDulaglutide was linked to greater PBR improvement than DDP-4i in patients with diabetes and fatty liver.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePBR improvement
Study
n = 41
Comparator
DDP-4i
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide showed greater improvement in GLS (22.6% vs. 8.5%, vs. 5.9%, P = 0.015) and PBR (P = 0.037) than dapagliflozin and DDP-4i.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
Report a problemFND-4220165604
05HumanObservational studyEfficacy outcome
In patients with T2DM and MASLD, dulaglutide increased CFR more than DDP-4i.
In plain wordsDulaglutide was linked to a greater coronary flow reserve increase than DDP-4i.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCoronary flow reserve
Study
n = 41
Comparator
DDP-4i
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Both dulaglutide and dapagliflozin showed a greater increase in CFR than DDP-4i post-treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
Report a problemFND-4220165605

Studies that did not test the peptide alone9

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, HbA1c decreased from baseline in all groups, including dulaglutide.
In plain wordsHbA1c decreased from baseline in all treatment groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared HbA1c decrease
Study
n = 62
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165606
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, BMI decreased from baseline in all groups, including dulaglutide.
In plain wordsBMI decreased from baseline in all treatment groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared BMI decrease
Study
n = 62
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165607
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, central SBP decreased from baseline in all groups, including dulaglutide.
In plain wordsCentral blood pressure decreased from baseline in all groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared central SBP decrease
Study
n = 62
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165608
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, PBR decreased from baseline in all groups, including dulaglutide.
In plain wordsPBR decreased from baseline in all treatment groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared PBR decrease
Study
n = 62
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165609
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, PWV decreased from baseline in all groups, including dulaglutide.
In plain wordsPulse wave velocity decreased from baseline in all groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared PWV decrease
Study
n = 62
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165610
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, CAP decreased from baseline in all groups, including dulaglutide.
In plain wordsThe liver fat measure decreased from baseline in all groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared CAP decrease
Study
n = 62
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165611
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, liver stiffness decreased from baseline in all groups, including dulaglutide.
In plain wordsLiver stiffness decreased from baseline in all groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseShared liver stiffness decrease
Study
n = 62
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
At baseline and after 12 months, we assessed the perfused boundary region (PBR) as a marker of glycocalyx thickness, peripheral and central systolic blood pressure (cSBP), pulse wave velocity (PWV), coronary flow reserve (CFR), left ventricular global longitudinal strain (GLS), controlled attenuatio…
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165612
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, CFR increased from baseline in all groups, including dulaglutide.
In plain wordsCoronary flow reserve increased from baseline in all groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseShared CFR increase
Study
n = 62
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165613
14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM with MASLD, GLS increased from baseline in all groups, including dulaglutide.
In plain wordsGLS increased from baseline in all treatment groups, including dulaglutide. This does not isolate dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseShared GLS increase
Study
n = 62
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
At 12 months, all patients had reduced glycosylated hemoglobin and body mass index compared to baseline (P < 0.001), as well as a significant reduction in cSBP, PBR, PWV, CAP, E, and increase in CFR and GLS (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an unblinded real-world study using propensity score analysis of consecutive patients with T2DM and MASLD received either SGLT-2i (dapagliflozin; n = 21), GLP-1RA (dulaglutide; n = 21), or dipeptidyl peptidase-4 inhibitors (DPP-4i; n = 20).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4220165614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.